Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia.
作者信息
Locatelli Franco, Whitlock James A, Peters Christina, Chen-Santel Christiane, Chia Victoria, Dennis Robyn M, Heym Kenneth M, Katz Aaron J, Kelsh Michael A, Sposto Richard, Tu Huakang, Tuglus Catherine A, Verma Anupam, Vinti Luciana, Wilkes Jennifer J, Zubarovskaja Nathalya, Zugmaier Gerhard, von Stackelberg Arend, Sun Weili
机构信息
Department of Pediatric Hematology/Oncology and of Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Sapienza University of Rome, Rome, Italy.
The Hospital for Sick Children/University of Toronto, Toronto, ON, Canada.
出版信息
Leukemia. 2020 Sep;34(9):2473-2478. doi: 10.1038/s41375-020-0770-8. Epub 2020 Feb 24.
Abstract
摘要
相似文献
1
Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia.在复发/难治性Ph阴性B细胞前体急性淋巴细胞白血病儿童患者中，博纳吐单抗与历史标准疗法的对比研究
Leukemia. 2020 Sep;34(9):2473-2478. doi: 10.1038/s41375-020-0770-8. Epub 2020 Feb 24.
2
Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data.利用历史数据评估接受博纳吐单抗治疗的费城染色体阴性复发/难治性B前体急性淋巴细胞白血病成人患者的长期生存率。
Adv Ther. 2017 Jan;34(1):148-155. doi: 10.1007/s12325-016-0447-x. Epub 2016 Nov 21.
3
Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.从美国医保支付方角度看，博纳吐单抗与挽救性化疗用于复发或难治性费城染色体阴性B前体急性淋巴细胞白血病的成本效益
J Med Econ. 2017 Sep;20(9):911-922. doi: 10.1080/13696998.2017.1344127. Epub 2017 Jul 11.
4
Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study.费城染色体阳性 B 细胞前体急性淋巴细胞白血病患者接受blinatumomab 治疗的长期随访：ALCANTARA 研究的最终分析。
Eur J Cancer. 2021 Mar;146:107-114. doi: 10.1016/j.ejca.2020.12.022. Epub 2021 Feb 13.
5
FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.FDA 补充批准：blinatumomab 用于治疗复发/难治性前体 B 细胞急性淋巴细胞白血病。
Oncologist. 2018 Nov;23(11):1366-1371. doi: 10.1634/theoncologist.2018-0179. Epub 2018 Jul 17.
6
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.儿童移植后复发/难治性B前体急性淋巴细胞白血病通过使用T细胞接合双特异性抗体博纳吐单抗治疗显示出持久缓解。
Haematologica. 2014 Jul;99(7):1212-9. doi: 10.3324/haematol.2013.100073. Epub 2014 Apr 11.
7
Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia.复发/难治性B前体急性淋巴细胞白血病患者复发后使用博纳吐单抗进行再治疗。
Leukemia. 2018 Feb;32(2):562-565. doi: 10.1038/leu.2017.306. Epub 2017 Oct 9.
8
Venetoclax and blinatumomab based chemotherapy-free treatment in a patient with Philadelphia chromosome-negative acute lymphoblastic leukemia.维奈托克和博纳吐单抗用于一名费城染色体阴性急性淋巴细胞白血病患者的无化疗治疗
Ann Hematol. 2023 May;102(5):1275-1277. doi: 10.1007/s00277-023-05127-3. Epub 2023 Mar 9.
9
A balancing act: Blinatumomab use in a rare occurrence of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia in an adolescent patient with Down syndrome.一种平衡行为：在一名患有唐氏综合征的青少年患者罕见的费城染色体阳性B细胞急性淋巴细胞白血病中使用博纳吐单抗。
Pediatr Blood Cancer. 2023 May;70(5):e30191. doi: 10.1002/pbc.30191. Epub 2023 Jan 5.
10
Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia.Blinatumomab 治疗费城染色体阴性、前体 B 细胞急性淋巴细胞白血病。
Clin Cancer Res. 2015 Oct 1;21(19):4262-9. doi: 10.1158/1078-0432.CCR-15-0125. Epub 2015 Aug 17.
引用本文的文献
1
Efficacy of Blinatumomab in Pediatric Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.博纳吐单抗治疗儿童急性淋巴细胞白血病的疗效：随机对照试验的系统评价和荟萃分析
Cureus. 2025 Jun 18;17(6):e86260. doi: 10.7759/cureus.86260. eCollection 2025 Jun.
2
Immunotherapy-related neurotoxicity in the central nervous system of children with cancer.癌症患儿中枢神经系统中与免疫治疗相关的神经毒性
Neuro Oncol. 2025 Mar 7;27(3):625-643. doi: 10.1093/neuonc/noae243.
3
Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.Tisagenlecleucel 对比儿童和青少年复发/难治性 B 细胞前体急性淋巴细胞白血病患者的历史标准治疗。
Leukemia. 2023 Dec;37(12):2346-2355. doi: 10.1038/s41375-023-02042-4. Epub 2023 Oct 25.
4
Harnessing the Immune System: Current and Emerging Immunotherapy Strategies for Pediatric Acute Lymphoblastic Leukemia.利用免疫系统：小儿急性淋巴细胞白血病的当前及新兴免疫治疗策略
Biomedicines. 2023 Jul 3;11(7):1886. doi: 10.3390/biomedicines11071886.
5
Acute Lymphoblastic Leukemia Immunotherapy Treatment: Now, Next, and Beyond.急性淋巴细胞白血病免疫治疗：现状、未来及展望。
Cancers (Basel). 2023 Jun 26;15(13):3346. doi: 10.3390/cancers15133346.
6
[Chinese expert consensus of allogeneic hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia (2022)].《儿童急性淋巴细胞白血病异基因造血干细胞移植中国专家共识（2022年版）》
Zhonghua Xue Ye Xue Za Zhi. 2022 Oct 14;43(10):793-801. doi: 10.3760/cma.j.issn.0253-2727.2022.10.001.
7
Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/ Rearrangements in a Modern Therapy Era: A Retrospective International Study.现代治疗时代伴有 11q23/重排的儿童非婴儿急性淋巴细胞白血病的结局：一项回顾性国际研究。
J Clin Oncol. 2023 Mar 1;41(7):1404-1422. doi: 10.1200/JCO.22.01297. Epub 2022 Oct 18.
8
Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era.小儿复发性或难治性急性B细胞系淋巴细胞白血病的新型治疗方法：精准医学时代
Front Pediatr. 2022 Jun 23;10:923419. doi: 10.3389/fped.2022.923419. eCollection 2022.
9
The EHA Research Roadmap: Malignant Lymphoid Diseases.欧洲血液学协会研究路线图：恶性淋巴疾病
Hemasphere. 2022 May 19;6(6):e726. doi: 10.1097/HS9.0000000000000726. eCollection 2022 Jun.
10
Development of CAR T Cell Therapy in Children-A Comprehensive Overview.儿童嵌合抗原受体T细胞疗法的发展——全面概述
J Clin Med. 2022 Apr 12;11(8):2158. doi: 10.3390/jcm11082158.
Zotero 插件